Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

HAL-MPE1 Safety and Tolerability Study

ClinicalTrials.gov ID: NCT02991885

Public ClinicalTrials.gov record NCT02991885. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Safety, Tolerability and Immunologic Effects of HAL-MPE1 Subcutaneous Immunotherapy in Adult and Paediatric Subjects With Peanut Allergy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.

Study identification

NCT ID
NCT02991885
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
HAL Allergy
Industry
Enrollment
42 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
5 Years to 50 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2016 (Actual)
Primary completion
Apr 2019 (Actual)
Completion
Sep 2019 (Actual)
Last update posted
Feb 19, 2020

2016 – 2019

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
John Hopkins Hospital University-Divison of Pediatric Allergy Baltimore Maryland 21287 —
Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai New York New York 10029 —
UNC Rheumatolory Allergy & Immunology Clinic Chapel Hill North Carolina 27517 —
Allergy, Asthma and Immunology Center Tulsa Oklahoma 74136 —
South Texas Allergy & Asthma Medical Professionals (STAAMP) San Antonio Texas 78251 —
Asthma, Inc. Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02991885, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 19, 2020 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02991885 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →